



PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/735,461-Conf. #3119

Filing Date December 11, 2003

First Named Inventor Michael P. CZECH

Art Unit 1635

Examiner Name R. A. Schnizer

Attorney Docket Number UMY-055

ENCLOSURES (Check all that apply)☒ Fee Transmittal Form☐ Fee Attached☐ Amendment/Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Reply to Missing Parts/
Incomplete Application☐ Reply to Missing Parts under
37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a
Provisional Application☐ Power of Attorney, Revocation
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ Landscape Table on CD☐ After Allowance Communication
to TC☐ Appeal Communication to Board of
Appeals and Interferences☐ Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please
Identify below):Return Receipt Postcard
PTO form SB/08
Certificate of Mailing
Copies of Seventeen (17)
References

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name LAHIVE & COCKFIELD, LLP

Signature

Printed name Debra J. Milasincic, Esq.

Date July 9, 2007

Reg. No. 46,931

Express Mail Label No. EV 956462079 US Dated: July 9, 2007



PTO/SB/17 (08-07)

Approved for use through 06/30/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).**FEE TRANSMITTAL**
For FY 2007☒ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT**(\$)
180.00**Complete if Known**

Application Number	10/735,461-Conf. #3119
Filing Date	December 11, 2003
First Named Inventor	Michael P. CZECH
Examiner Name	R. A. Schnizer
Art Unit	1635
Attorney Docket No.	UMY-055

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify):☒ Deposit Account Deposit Account Number: 12-0080 Deposit Account Name: Lahive & Cockfield, LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	Fee (\$)	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
		Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	
Utility	300	150	500	250	200	100		
Design	200	100	100	50	130	65		
Plant	200	100	300	150	160	80		
Reissue	300	150	500	250	600	300		
Provisional	200	100	0	0	0	0		

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity	Fee (\$)
Each claim over 20 (including Reissues)	50	25	
Each independent claim over 3 (including Reissues)	200	100	
Multiple dependent claims	360	180	

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
---------------------	---------------------	-----------------	----------------------

-	=	x	=
---	---	---	---

HP = highest number of total claims paid for, if greater than 20.

<u>Indep. Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
----------------------	---------------------	-----------------	----------------------

-	=	x	=
---	---	---	---

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
---------------------	---------------------	---	-----------------	----------------------

- 100 =	/50 =	(round up to a whole number) x	=	
---------	-------	--------------------------------	---	--

4. OTHER FEE(S)

Non-English Specification: \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00

SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	46,931	Telephone	(617) 227-7400
Name (Print/Type)	Debra J. Milasincic, Esq.	Date	July 9, 2007		

Express Mail Label No. EV 956462079 US Dated: July 9, 2007



07-10-07

DFW #

Express Mail Label No. EV 956462079 US Dated: July 9, 2007

Docket No.: UMY-055
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Michael P. Czech *et al.*

Application No.: 10/735,461

Confirmation No.: 3119

Filed: December 11, 2003

Art Unit: 1635

For: METHOD OF INTRODUCING siRNA INTO
ADIPOCYTES

Examiner: R. A. Schnizer

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have not submitted a copy of the cited U.S. patent application in accordance with 37 CFR 1.98(a)(2)(ii). Applicants submit herewith copies of foreign patents and non-patent references in accordance with 37 CFR 1.98(a)(2).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

07/10/2007 TNGUYEN2 00000034 120080 10735461

01 FC:1806 180.00 DA


This Information Disclosure Statement is filed after the mailing date of a Final Office Action but before payment of the Issue Fee (37 CFR 1.97(d)). Applicants hereby petition that the Information Disclosure Statement be considered.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. UMY-055.

Dated: July 9, 2007

DJM/MBC/mch

Respectfully submitted,

By 
Debra J. Milasincic, Esq.
Registration No.: 46,931
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant



Application No. (if known): 10/735,461

Attorney Docket No.: UMY-055

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 956462079 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on July 9, 2007
Date

Signature

Debra J. Milasincic, Esq.

Typed or printed name of person signing Certificate

46,931

Registration Number, if applicable

(617) 227-7400

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard
Transmittal (1 page)
Fee Transmittal (1 page, in duplicate)
Supplemental Information Disclosure Statement (2 pages)
PTO form SB/08 (18 References) (2 pages)
Copies of Seventeen (17) References



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/735,461-Conf. #3119	
			Filing Date	December 11, 2003	
			First Named Inventor	Michael P. CZECH	
			Art Unit	1635	
			Examiner Name	R. A. Schnizer	
Sheet	1	of	2	Attorney Docket Number	UMY-055

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-20020162126-A1	10-31-2002	Beach et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-99/32619-A1	07-01-1999	The Carnegie Institute of Washington et al		
	B2	WO-99/54465-A2	10-28-1999	Warner-Lambert Company et al.		
	B3	WO-00/31291-A1	06-02-2000	Pharmacia & Upjohn AB		
	B4	WO-01/75164-A2	10-11-2001	Whitehead Institute for Biomedical Research et al		
	B5	WO-01/93669-A2	12-13-2001	Devgen NV		
	B6	WO-02/33046-A2	04-25-2002	University of Massachusetts		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Bose, Avirup et al., "Gα11 Signaling through ARF6 Regulates F-Actin Mobilization and GLUT4 Glucose Transporter Translocation to the Plasma Membrane," <i>Molecular and Cellular Biology</i> , Vol. 21(15):5262-5275 (2001)	
	C2	Bose, Avirup et al., "Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c," <i>Nature</i> , Vol. 420(6917):821-824 (2002)	
	C3	Czauderna, Frank et al., "Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA," <i>Nucleic Acids Research</i> , Vol. 31(2):670-682 (2003)	
	C4	Elbashir, Sayda M. et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , Vol. 26:199-213 (2002)	
	C5	Izuishi, Kunihiko et al., "Remarkable Tolerance of Tumor Cells to Nutrient Deprivations: Possible New Biochemical Target for Cancer Therapy," <i>Cancer Research</i> , Vol. 60:6201-6207 (2000)	
	C6	Min, Jing et al., "Synip: A Novel Insulin-Regulated Syntaxin 4-Binding Protein Mediating GLUT4 Translocation in Adipocytes," <i>Molecular Cell</i> , Vol. 3:751-760 (1999)	
	C7	Paradis, Suzanne et al., " <i>Caenorhabditis elegans</i> Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor," <i>Genes & Development</i> , Vol. 12:2488-2498 (1998)	
	C8	Siegmund, Daniela et al., "Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced Apoptosis," <i>Molecular Medicine</i> , Vol. 8(11):725-732 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/735,461-Conf. #3119
				Filing Date	December 11, 2003
				First Named Inventor	Michael P. CZECH
				Art Unit	1635
				Examiner Name	R. A. Schnizer
Sheet	2	of	2	Attorney Docket Number	UMY-055

	C9	Tuschl, Thomas et al., "Small Interfering RNAs: A Revolutionary Tool for the analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , Vol. 2(3):158-167 (2002)	
	C10	Walters, D.K. et al., "The Effectiveness of Double-Stranded Short Inhibitory RNAs (siRNAs) May Depend on the Method of Transfection," <i>Antisense and Nucleic Acid Drug Development</i> , Vol. 12:411-418 (2002)	
	C11	Weil, D. et al., "Targeting the Kinesin Eg5 to Monitor siRNA Transfection in Mammalian Cells," <i>BioTechniques</i> , Vol. 33(6):1244-1248 (2002)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--